← Back to Search

Non-Nucleoside Reverse Transcriptase Inhibitor

Nelfinavir vs Efavirenz for HIV

Phase 4
Waitlist Available
Research Sponsored by Agouron Pharmaceuticals
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights

Study Summary

This trial will compare the effectiveness of two drugs used to treat HIV.

Who is the study for?
This trial is for HIV-positive individuals who have never been treated with anti-HIV drugs. They must have a CD4 count of at least 100 cells/mm3 and a viral load of at least 5,000 copies/ml to participate.Check my eligibility
What is being tested?
The study compares two anti-HIV medications: Nelfinavir (NFV) and Efavirenz (EFV). It aims to determine which drug is more effective in maintaining low levels of HIV in the blood and improving immune system response.See study design
What are the potential side effects?
Potential side effects may include digestive issues, changes in body fat distribution, skin rashes, dizziness, trouble sleeping, increased cholesterol or triglyceride levels, and possible resistance to medication if not taken as prescribed.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Find a Location

Who is running the clinical trial?

Agouron PharmaceuticalsLead Sponsor
16 Previous Clinical Trials
2,061 Total Patients Enrolled

Media Library

Efavirenz (Non-Nucleoside Reverse Transcriptase Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT00005000 — Phase 4
Human Immunodeficiency Virus Infection Research Study Groups:
Human Immunodeficiency Virus Infection Clinical Trial 2023: Efavirenz Highlights & Side Effects. Trial Name: NCT00005000 — Phase 4
Efavirenz (Non-Nucleoside Reverse Transcriptase Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT00005000 — Phase 4

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does my profile align with the parameters for this research endeavor?

"To meet the eligibility requirements of this research, applicants must have an HIV diagnosis and be aged between 0 to 18. A maximum recruitment size of 200 individuals is being targeted by the trial organisers."

Answered by AI

Does this research venture accept individuals aged above 20?

"This medical trial explicitly specifies that only individuals aged between 0 and 18 are eligible to participate. Moreover, there are 108 other trials tailored for minors, as well as 352 specifically designed for seniors."

Answered by AI

Is the enrollment process for this investigation still open?

"As per the information affixed on clinicaltrials.gov, this medical experiment is no longer recruiting patients. Originally posted in December of 1999 with its last revision being June 23rd 2005; however, there are currently 484 other trials that need participants at this moment."

Answered by AI

Are there any official regulatory endorsements for this therapy?

"This treatment has already received approval, so it is given a score of 3 on the safety scale."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
Treatment With Nelfinavir or Efavirenz of HIV-Infected Patients Who Have Never Received Anti-HIV Drugs
1999. "Treatment With Nelfinavir or Efavirenz of HIV-Infected Patients Who Have Never Received Anti-HIV Drugs". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT00005000.
All > Hiv Infection > Cte
~8 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top